drug · small molecule

NICARDIPINE HYDROCHLORIDE

Marketedupdated 5mo ago

by $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for hypertension and 3 investigational indications.

indications

investigational

Hypertension

targets

Voltage-gated L-type calcium channel

all catalysts(4)

approval · 4

Sep 6, 2024

approval

2y ago

NICARDIPINE HYDROCHLORIDE — FDA approval

NICARDIPINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE — FDA approval

NICARDIPINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE — FDA approval

NICARDIPINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE — FDA approval

NICARDIPINE HYDROCHLORIDE

→

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 18, 2027

200 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (22)

Dec 26, 2027formulationUS 76121021.2y
Dec 26, 2027formulationUS 76121021.2y
Dec 26, 2027formulationUS 76121021.2y
Dec 26, 2027formulationUS 76121021.2y
Dec 26, 2027formulationUS 93645641.2y
Dec 26, 2027formulationUS 93645641.2y
Dec 26, 2027formulationUS 93645641.2y
Dec 26, 2027formulationUS 93645641.2y
Apr 18, 2027formulationUS 10758616200d
Apr 18, 2027formulationUS 10758616200d
Apr 18, 2027formulationUS 10758616200d
Apr 18, 2027method-of-use (U-1029)US 11547758200d
Apr 18, 2027method-of-use (U-1029)US 11547758200d
Apr 18, 2027method-of-use (U-1029)US 11547758200d
Apr 18, 2027method-of-use (U-1029)US 7659291200d
Apr 18, 2027method-of-use (U-1029)US 7659291200d
Apr 18, 2027method-of-use (U-1029)US 7659291200d
Apr 18, 2027method-of-use (U-1029)US 7659291200d
Apr 18, 2027method-of-use (U-1029)US 8455524200d
Apr 18, 2027method-of-use (U-1029)US 8455524200d
Apr 18, 2027method-of-use (U-1029)US 8455524200d
Apr 18, 2027method-of-use (U-1029)US 8455524200d

News(0)

no news has mentioned this drug yet

brand

NICARDIPINE HYDROCHLORIDE

trade names

Cardene, Cardene sr, Nicardipine hydrochloride

generic

NICARDIPINE HYDROCHLORIDE

MOA

Mechanism of Action Nicardipine hydrochloride capsules are a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine hydrochloride capsules are more selective to vascular smooth muscle than cardiac muscle. In animal models, Nicardipine hydrochloride capsules produce relaxation of coronary vascular smooth muscle at drug levels that cause little or no negative inotropic effect.

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

NICARDIPINE HYDROCHLORIDE

Marketedupdated 5mo ago

by $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for hypertension and 3 investigational indications.

indications

investigational

Hypertension

targets

Voltage-gated L-type calcium channel

all catalysts(4)

approval · 4

Sep 6, 2024

approval

2y ago

NICARDIPINE HYDROCHLORIDE — FDA approval

NICARDIPINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE — FDA approval

NICARDIPINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE — FDA approval

NICARDIPINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE — FDA approval

NICARDIPINE HYDROCHLORIDE

→

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 18, 2027

200 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (22)

Dec 26, 2027formulationUS 76121021.2y
Dec 26, 2027formulationUS 76121021.2y
Dec 26, 2027formulationUS 76121021.2y
Dec 26, 2027formulationUS 76121021.2y
Dec 26, 2027formulationUS 93645641.2y
Dec 26, 2027formulationUS 93645641.2y
Dec 26, 2027formulationUS 93645641.2y
Dec 26, 2027formulationUS 93645641.2y
Apr 18, 2027formulationUS 10758616200d
Apr 18, 2027formulationUS 10758616200d
Apr 18, 2027formulationUS 10758616200d
Apr 18, 2027method-of-use (U-1029)US 11547758200d
Apr 18, 2027method-of-use (U-1029)US 11547758200d
Apr 18, 2027method-of-use (U-1029)US 11547758200d
Apr 18, 2027method-of-use (U-1029)US 7659291200d
Apr 18, 2027method-of-use (U-1029)US 7659291200d
Apr 18, 2027method-of-use (U-1029)US 7659291200d
Apr 18, 2027method-of-use (U-1029)US 7659291200d
Apr 18, 2027method-of-use (U-1029)US 8455524200d
Apr 18, 2027method-of-use (U-1029)US 8455524200d
Apr 18, 2027method-of-use (U-1029)US 8455524200d
Apr 18, 2027method-of-use (U-1029)US 8455524200d

News(0)

no news has mentioned this drug yet

brand

NICARDIPINE HYDROCHLORIDE

trade names

Cardene, Cardene sr, Nicardipine hydrochloride

generic

NICARDIPINE HYDROCHLORIDE

MOA

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

NICARDIPINE HYDROCHLORIDE

🐶 often sniffed alongside

indications

targets

all catalysts(4)

Patent cliff

patents (22)

News(0)

Report a data issue

comments(0)

NICARDIPINE HYDROCHLORIDE

🐶 often sniffed alongside

indications

targets

all catalysts(4)

Patent cliff

patents (22)

News(0)

Report a data issue

comments(0)